ClinicalTrials.Veeva

Menu

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

S

Sun Ying-Shi

Status

Completed

Conditions

Locally Advanced Rectal Cancer

Treatments

Diagnostic Test: pelvic MR examination

Study type

Observational

Funder types

Other

Identifiers

NCT03238885
RCpCR-MR-Radiomics

Details and patient eligibility

About

This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.

Full description

We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The ultimate aim is to select appropriate LARC patients for omission of surgery.

Enrollment

538 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • pathologically proved rectal cancer
  • locally advanced rectal cancer (≥T3 or N+)
  • a distance less than 12cm between the lower edge of tumor and the anal margin
  • no evidence of distant metastases
  • no prior anti-cancer therapy before treatment
  • scheduled to receive preoperative CRT

Exclusion criteria

  • history or concurrent of other malignancy
  • incomplete preoperative CRT
  • failed to receive surgery or unavailable pCR assessment
  • poor quality of MR images for measurement
  • patient quit

Trial design

538 participants in 1 patient group

LARC-CRT
Description:
LARC patients who will receive neoadjuvant CRT before surgical resection.
Treatment:
Diagnostic Test: pelvic MR examination

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems